Abbelight Secures Series B Funding to Expand Super-Resolution Microscopy Technology for Drug Discovery Applications
核心洞察
Abbelight (搜索), a Paris-based super-resolution microscopy (搜索) company, closed a Series B financing round led by AVANT BIO (搜索) to accelerate product innovation and commercial expansion.
The company plans to tailor its imaging technology for new applications including single-cell phenotyping and mechanism-of-action validation in drug discovery.
Founded in 2016, Abbelight (搜索) currently serves over 100 installed systems across public research institutes and biotech companies with its single-molecule localization microscopy (搜索) solutions.
Abbelight (搜索), a global leader in super-resolution microscopy (搜索) solutions, announced the successful completion of a Series B financing round led by AVANT BIO (搜索), a growth equity firm focused on enabling technologies for therapeutics development. The Paris-based company plans to use the funding to accelerate product innovation and expand commercial adoption of its nanoscale imaging systems across a broader customer base.
Expanding Into Drug Discovery Applications
The company develops end-to-end super-resolution imaging systems and "sample-to-insight" workflows that combine chemistry, optics and data analysis to help researchers visualize and quantify biological processes at the nanoscale. With this new funding, Abbelight (搜索) plans to tailor its imaging toolbox for additional growth verticals, including single-cell phenotyping and mechanism-of-action validation in drug discovery.
"With a decade of experience in the Life Science Research market, Abbelight (搜索) has been transforming the way scientists see, quantify, and interpret all kinds of complex intracellular mechanisms," said Nicolas Bourg, CTO and Co-Founder of Abbelight. "It's now time to tailor our cutting-edge imaging toolbox to also address new key verticals, such as single cell phenotyping and mechanisms of action validation for drug discovery."
Commercial Expansion Strategy
Founded in 2016, Abbelight (搜索) employs approximately 60 people and focuses on single-molecule localization microscopy (搜索) (SMLM) and related nanoscopy technologies. The company currently serves both public research institutes and biotech customers, with more than 100 systems installed across its customer base.
The funding is expected to support commercial expansion and customer support as Abbelight (搜索) scales beyond its existing installed base. The company aims to increase adoption across the broader bioindustry, including biopharma, biotech and contract research organizations.
"This is an exciting moment for Abbelight (搜索). The funding accelerates our commercial expansion and allows us to continue delivering best-in-class support to our 100+ installed base," said Jean-Baptiste Marie, CEO and co-founder. "AVANT BIO (搜索)'s support will be key to driving innovation and adoption across the broader bioindustry, including biopharma, biotech, and CROs."
Technology Impact on Life Sciences
AVANT BIO (搜索)'s investment reflects the growing importance of advanced imaging technologies in life sciences research and drug development. The firm specializes in enabling technologies that shape how therapeutics are discovered, developed, and manufactured.
"Big things happen at the nanoscale – and Abbelight (搜索) enables researchers to visualize precise sub-cellular structures like never before," said Daniella Kranjac, Founding General Partner at AVANT BIO (搜索). "Their breakthroughs in super-resolution microscopy (搜索) and sample-to-insight workflows embody the kind of enabling technologies that accelerate discovery and drive innovation across life sciences."
The investment positions Abbelight (搜索) to capitalize on the increasing demand for high-resolution imaging solutions in pharmaceutical research, particularly as the industry seeks more precise tools for understanding cellular mechanisms and validating drug targets at the molecular level.